Abbott Laboratories (ABT) Long-Term Debt Repayments (2010 - 2026)

Abbott Laboratories has reported Long-Term Debt Repayments for 15 years, with the latest figure at $1.4 billion in Q2 2026.

• Quarterly Long-Term Debt Repayments rose 140400.0% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 billion (up 225.15% YoY) and the FY2021 annual result came in at $48.0 million, down 96.4% from the prior year.
• Long-Term Debt Repayments retreated to $1.4 billion in Q2 2026 per ABT's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Long-Term Debt Repayments peaked at $1.4 billion in Q3 2023 and troughed at $1.0 million in Q2 2022.
• A 5-year average of $545.3 million and a median of $259.5 million in 2024 frame the typical range for Long-Term Debt Repayments.
• The sharpest annual moves came in 2023 and 2024: Long-Term Debt Repayments soared 144400.0% in 2023, then sank 99.86% in 2024.
• Over 5 years, Long-Term Debt Repayments stood at $1.0 million in 2022, then jumped by 144400.0% to $1.4 billion in 2023, then tumbled by 99.86% to $2.0 million in 2024, then soared by 24950.0% to $501.0 million in 2025, then surged by 180.44% to $1.4 billion in 2026.
• According to Business Quant data, Long-Term Debt Repayments over the past three periods registered $1.4 billion, $1.4 billion, and $501.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.